Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Acorda Therapeutics
Most Recent Events
- 20 Sep 2018 New trial record